Philley..., by the year’s end, not only will PTX have 4 concurrent clinical trials active (including the imminent ptx100 pilot study), but furthermore progressive results on both the AML and the Ovarian cancer phase 1 conclusions.
With the current market cap approximately 20-30mil, as u previously predicted, potential re-rate is imminent.
The catalyst of milestones of 2018 will filter favourably to those who hold (IMO).
P.s. unlike other biotech companies, management strategically and simultaneous are currently into phase 2 on both the breastcancer and AML studies, and not in wait pause/design/ placement mode conventional mentality.
Happy to hold (and , as funds come my way, keep accumulating).
PTX Price at posting:
10.5¢ Sentiment: Buy Disclosure: Held
